GMP Compliance for Production of CB.Hep-1 Monoclonal Antibody as a Biological Reagent - - BioPharm International


GMP Compliance for Production of CB.Hep-1 Monoclonal Antibody as a Biological Reagent


Figure 4. Standard Operating Procedures. List of the SOPs that describe the main operations of the production of anti-HBsAg monoclonal antibody and the immunoaffinity matrix.
Documentation is the key to a consistent, controlled process according to Vasilevsky.12 The documentation system is integrated with different documents approved by the Quality Assurance (QA) department following GMP requirements. These include: Standard Operation Procedures (SOP), quality specifications, batch production records, the legal license to produce, as well as other documents such as flowcharts, cleaning standards, calibration and equipment maintenance records.

In addition, organization and personnel-related detail is included, such as: organization charts of the production department, descriptions of all the positions and responsibilities, as well as control lines and subordination. Behavior, hygiene, manners, and the training of personnel are described in detail in the organization and personnel data.

Results and Discussion

Figure 5. The Main Guides, Codes, and Regulations for the Production of MAbs Antibodies
Guidelines for the development of MAbs are published and periodically updated. (See Figure 5.) These guidelines serve as blueprints for the manufacture, safety, and efficacy testing of MAbs. Because biotechnology and the development of MAbs are rapidly evolving fields, the information contained in these guidelines may become obsolete or be subject to rapid change as new and more significant information becomes available.

The enclosed table, keeping in mind the guidelines issued by the World Health Organization (WHO) and FDA, enables us to see the guidelines for MAbs used as reagents and parenteral therapeutics. The regulations on the use of monoclonal antibodies are the same in both cases; its demanding features are the same. (See Figure 5)

WHO Technical Report Series 822

This document applies to murine and human monoclonal antibodies for use in humans, including in vivo diagnosis and ex vivo (extra corporeal) treatment. It is recommended that monoclonal antibodies intended for use in the preparation of biological products in humans should also meet these requirements, except those relating to the final product. (This document is not concerned with the production of monoclonal antibodies by recombinant DNA techniques, such as "humanized" antibodies, nor with monoclonal antibodies to be used for in vitro diagnostic purposes.)

Food and Drug Adminis-tration (FDA) 1997

The FDA documents apply to MAb used as therapeutic or in vivo diagnostic agents, as well as to ancillary products, i.e., MAb used in the manufacture of other products for in vivo use. The latter include MAb that are used alone or in conjunction with devices, for example, for ex vivo purging of cells to remove immune or tumor cells, for ex vivo collection (e.g., hematopoietic cells), or for purification of other products intended for in vivo administration. Generally, these MAb should meet the same criteria for safety and freedom from adventitious agents as MAb intended for direct administration to patients.

blog comments powered by Disqus



Bristol-Myers Squibb and Five Prime Therapeutics Collaborate on Development of Immunomodulator
November 26, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
Author Guidelines
Source: BioPharm International,
Click here